Is Vertex Pharmaceuticals Incorporated (VRTX) Fairly Valued?
Vertex Pharmaceuticals Incorporated valuation review using P/E, fair value, revenue growth, EPS growth, net margin, and TGMCharts chart exhibits as of July 10, 2026.
By TGMCharts Research · Data as of · Updated
Evaluating Vertex Pharmaceuticals Incorporated requires balancing its premium trailing multiple of 28.79x against an analyst DCF (FMP) fair-value reference of $412, which places the market price above the calculated intrinsic value.
The market's willingness to pay a premium multiple is anchored by a five-year revenue CAGR of 14.24% and a five-year EPS CAGR of 8.17%. Combined with a high-quality net margin of 35.40%, these operational metrics must remain durable to sustain current pricing.
- Vertex Pharmaceuticals Incorporated closed at $485 on July 10, 2026.
- Trailing P/E is 28.79x and price-to-sales is 10.15x.
- Analyst DCF (FMP) is $412 with margin of safety at -15.14%.
- Five-year revenue CAGR is 14.24% and five-year EPS CAGR is 8.17%.
- Earnings yield is 3.47% and net margin is 35.40%.
Valuation Setup
The market price, model anchor, growth support, and profitability facts behind the valuation read.
The Core Valuation Question Facing Vertex Investors
As of July 10, 2026, Vertex Pharmaceuticals Incorporated presents a classic valuation puzzle where a premium market multiple must be weighed against high-quality operational execution. With the equity closing at $485, the market has assigned a trailing price-to-earnings multiple of 28.79x. This premium rating must be evaluated alongside the consensus analyst-DCF (FMP) model, which places fair value at $412, implying a negative margin of safety of -15.14%.
To determine whether this premium is justified, we must look beyond a single ratio. This analysis examines the interplay between the company's market multiples, historical cash flows, and underlying business fundamentals. If the compounding power of the business matches the premium multiple, the current pricing remains defensible; if growth or profitability shows signs of deceleration, the valuation risk increases.
How the Market Multiples Align Across Sales and Earnings
The market's current appraisal of the business is reflected across several key valuation layers. The equity is valued at 10.15x times trailing sales, while offering an earnings yield of 3.47%. This yield represents the cash flow generation power relative to the market price and serves as a critical hurdle rate when compared to broader equity benchmarks.
VRTX P/E ratio Chart
The trailing earnings multiple is the main valuation exhibit because it connects the market price to reported earnings.
Latest P/E ratio: 28.79x as of July 10, 2026.
A P/E ratio of 28.79x has to be judged against the company's five-year EPS CAGR of 8.17%. If the multiple is high while EPS support is ordinary, the valuation thesis becomes more dependent on investor confidence than on fresh earnings power.
VRTX price-to-sales Chart
Price-to-sales gives a second valuation lens when margins and earnings can move around the cycle.
Latest price-to-sales ratio: 10.15x.
Price-to-sales at 10.15x is most useful beside net margin of 35.40%. A richer sales multiple is easier to defend when margin quality is durable rather than temporarily elevated.
Analyst Consensus Fair Value and the Implied Pricing Premium
The analyst-DCF (FMP) reference price of $412 serves as a useful external baseline for intrinsic value. Because the market price of $485 sits above this benchmark, the resulting margin of safety is -15.14%. Investors should treat this as a signal that the market is pricing in optimistic future developments that go beyond standard consensus cash flow projections.
The valuation at a glance
Each input on its own line: what the stock costs against earnings and sales, the model's fair value and how far price sits from it, and the growth and margins behind the business.
VRTX earnings yield Chart
Earnings yield reframes valuation from an owner's-yield perspective rather than a multiple perspective.
Latest earnings yield: 3.47%.
The earnings yield of 3.47% is the counterweight to the P/E ratio. If the yield is thin relative to the quality and growth profile, the valuation case needs more help from future compounding.
Evaluating the Growth Engine Behind the Premium Multiple
To sustain a trailing multiple of 28.79x, the underlying business must demonstrate robust expansion. Historically, the company has delivered on this front, posting a five-year revenue compound annual growth rate of 14.24%. This top-line expansion has translated effectively to the bottom line, with a five-year EPS CAGR of 8.17%, demonstrating operational leverage over the medium term.
VRTX revenue
Revenue history tests whether the valuation is being supported by real business expansion.
Five-year revenue CAGR: 14.24%. This is endpoint-to-endpoint from the fiscal years shown — a depressed start year can inflate it, so read it against the recent bars.
Revenue growth is the business-expansion evidence behind the valuation read. A five-year revenue CAGR of 14.24% helps show how much of the valuation story is coming from company growth instead of only multiple expansion.
VRTX EPS
EPS history checks whether reported earnings are keeping pace with the market multiple.
Five-year EPS CAGR: 8.17%. This is endpoint-to-endpoint from the fiscal years shown — a depressed or negative start year can inflate it, so read it against the recent bars.
A five-year EPS CAGR of 8.17% is the clearest support figure for a P/E-based conclusion. If EPS growth slows while the multiple remains elevated, the article should become more cautious after refresh.
Profitability Quality as a Defense for the Sales Multiple
A high price-to-sales ratio of 10.15x can be highly misleading without examining profit conversion. The company's net margin stands at 35.40%, showing that a substantial portion of every dollar of revenue flows directly to net income. This high level of profitability quality provides a strong buffer for the current valuation, though any structural pressure on margins would quickly make the sales multiple harder to defend.
VRTX net margin
Net margin shows whether the company has enough profitability quality to support its valuation.
Net margin (TTM): 35.40%. The bars below are annual fiscal years.
Net margin of 35.40% is a quality signal, not a valuation verdict by itself. It matters because a premium multiple is more defensible when margins are structurally strong and less defensible when margins are peaking.
The Balanced Bull and Bear Arguments for Vertex
The optimistic view of the valuation relies on the continuation of strong financial trends, specifically the five-year revenue CAGR of 14.24% and a net margin of 35.40% that indicates exceptional cash conversion. Conversely, the cautious perspective highlights that the market price has outpaced the analyst DCF (FMP) reference of $412, leaving no margin of safety if growth rates begin to normalize.
Bull and bear case
Valuation support
- Five-year revenue CAGR of 14.24% and five-year EPS CAGR of 8.17% support the business case.
- Net margin of 35.40% is the quality check behind the multiple.
Valuation pressure
- A P/E ratio of 28.79x can become demanding if EPS growth slows.
- The analyst-DCF (FMP) margin of safety at -15.14% should change the valuation read if it deteriorates after refresh.
Key Operational Metrics to Monitor for a Shift in Trend
The current valuation thesis would require reassessment under several conditions. A significant divergence in the analyst-DCF (FMP) fair value from $412 would directly alter the margin of safety calculations. Additionally, any deterioration in the five-year EPS CAGR of 8.17% or a contraction in the net margin below 35.40% would suggest that the fundamental support for the premium multiple is weakening.
Synthesizing the Fundamental and Market Evidence
In conclusion, the valuation of Vertex Pharmaceuticals Incorporated is a balance between a premium market multiple and exceptional operational metrics. With a net margin of 35.40% and solid historical growth, the business remains highly profitable, yet the negative margin of safety vs the analyst DCF (FMP) reference of $412 demands continued flawless execution. All data points in this note are verified against official filings and updated daily to maintain absolute factual integrity.
FAQ
Is VRTX fairly valued?
Vertex Pharmaceuticals Incorporated trades at 28.79x trailing earnings with an analyst-DCF (FMP) margin of safety of -15.14%. The cleanest read comes from comparing that valuation to five-year revenue CAGR of 14.24% and five-year EPS CAGR of 8.17%.
What valuation metric matters most for VRTX?
This article anchors on P/E, fair value, margin of safety, price-to-sales, earnings yield, revenue growth, and EPS growth. No single metric is treated as a recommendation.
How often should this VRTX valuation view refresh?
We refresh this note after each daily market close, so the price, fair value, and every figure stay current. Numbers here are as of July 10, 2026.
What would change our mind
- A material move away from the analyst-DCF (FMP) reference of $412.
- A break in five-year EPS support, currently 8.17%.
- Margin quality drifting away from the latest net margin of 35.40%.
The bottom line
Vertex Pharmaceuticals Incorporated valuation research note from TGMCharts Research, grounded in precomputed fundamentals, chart exhibits, and a frozen claim ledger.
Read next: VRTX fundamentalsContinue with Vertex Pharmaceuticals Incorporated's full stock page.How we checked this researchShowHide
Data snapshot · By TGMCharts Research.
Every number in this note comes from data we compute and store ourselves from the company's reported figures, plus verbatim excerpts from its SEC filings. When a value isn't available we say so — we never fill gaps with estimates.
Latest filing excerpt
10-Q · filed 2026-05-05 · period 2026-03-31 · SEC EDGAR source
- “Financial Highlights Total Revenues In the first quarter of 2026, our total revenues increased to $3.0 billion as compared to $2.8 billion in the first quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas.”
- “Non-Operating Income (Expense), Net Interest Income, Net Our net interest income of $114.8 million in the first quarter of 2026 was similar to $117.9 million of net interest income in the first quarter of 2025.”
- “Business Updates Marketed Products Cystic Fibrosis We expect that the number of people with CF taking our medicines will continue to grow through new approvals and reimbursement agreements, treatment of younger patients, increased survival and expansion into additional geographies.”
- “We are eligible to receive certain future milestone payments and tiered royalties on future net sales of povetacicept in these regions.”
Source pages
Exhibit sources
Research trail
Every number, checked
Every numeric or dated claim in this note was checked against our stored company data before publishing — each figure below links to the page it comes from.